RP-102124 / Revere Pharma - LARVOL DELTA

Discovery of a first-in-class allosteric inhibitor of the small GTPase Rac1 (AACR 2024) - "RP-102124 is orally bioavailable and shows dose dependent inhibition of tumor growth in xenograft models at doses that are well-tolerated. RP-102124 is a first-in-class allosteric Racmulti inhibitor that shows promising therapeutic potential."

Oncology • Solid Tumor • RAC1